Outcome according to presenting features in infant ALL treated with EORTC protocol #58881
| . | n . | EFS (%)* . | HR† . | P value . |
|---|---|---|---|---|
| Age | ||||
| Less than 6 mo | 34 | 30 | 1.7 | .13 |
| At least 6 mo | 26 | 56 | 1 | |
| WBC (×103/μL) | ||||
| Lower than 25 | 9 | 80 | 1 | |
| Lower than 100 | 16 | 57 | 4.1 | <.001 |
| At least 100 | 35 | 26 | 11.6 | |
| Prednisolone response | ||||
| Good (<1000/μL) | 38 | 48 | 1 | .02 |
| Poor (≥1000/μL) | 21 | 29 | 2.1 | |
| VHR feature | ||||
| No | 19 | 64 | 1 | .01 |
| Yes | 41 | 27 | 2.8 | |
| Immunophenotype | ||||
| CD10− | 39 | 29 | 3.7 | .02 |
| CD10+ | 11 | 79 | 1 | |
| CD34+ | 18 | 15 | 2.3 | .03 |
| CD34− | 21 | 56 | 1 | |
| Cytogenetics | ||||
| T(4;11) Yes | 26 | 23 | 2.5 | .01 |
| No | 23 | 63 | 1 |
| . | n . | EFS (%)* . | HR† . | P value . |
|---|---|---|---|---|
| Age | ||||
| Less than 6 mo | 34 | 30 | 1.7 | .13 |
| At least 6 mo | 26 | 56 | 1 | |
| WBC (×103/μL) | ||||
| Lower than 25 | 9 | 80 | 1 | |
| Lower than 100 | 16 | 57 | 4.1 | <.001 |
| At least 100 | 35 | 26 | 11.6 | |
| Prednisolone response | ||||
| Good (<1000/μL) | 38 | 48 | 1 | .02 |
| Poor (≥1000/μL) | 21 | 29 | 2.1 | |
| VHR feature | ||||
| No | 19 | 64 | 1 | .01 |
| Yes | 41 | 27 | 2.8 | |
| Immunophenotype | ||||
| CD10− | 39 | 29 | 3.7 | .02 |
| CD10+ | 11 | 79 | 1 | |
| CD34+ | 18 | 15 | 2.3 | .03 |
| CD34− | 21 | 56 | 1 | |
| Cytogenetics | ||||
| T(4;11) Yes | 26 | 23 | 2.5 | .01 |
| No | 23 | 63 | 1 |